Sesen Bio Nixes Reverse Stock Split Plan; Shares Rise
11:04AM ET 6/17/2022 MT NewswiresSesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...
Sesen Bio (SESN) said Friday that it is no longer seeking a reverse stock split of its common shares to avoid a potential delisting. The late-stage...
Sesen Bio (SESN) said Tuesday it has started reviewing strategic alternatives to maximize shareholder value. These options may include sale, merger,...
Address | 245 First Street Cambridge, Massachusetts 02142 |
Phone | +1.617.444.8550 |
Number of Employees | 24 |
Recent SEC Filing | 06/24/2022![]() |
President, Chief Executive Officer & Director | Thomas R. Cannell |
Chief Financial Officer & Treasurer | Monica Forbes |
Finance Director | Stephanie Vigue |
Head of Research | Jeannick Cizeau |
Price Open | $0.80 |
Previous Close | $0.80 |
52 Week Range | $0.37 - 6.04 |
Market Capitalization | $161.6 M |
Shares Outstanding | 199.5 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/08/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | 3.27 |
Earnings per Share | -$0.02 |
Beta vs. S&P 500 | N/A |
Revenue | $0.00 |
Net Profit Margin | 244.30% |
Return on Equity | 39.16% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |